Pharma Journalist -

Berkeley Lights, a life sciences tools company, and IsoPlexis, a company empowering labs to leverage the cells and proteome changing the course of human health, announced a definitive…
Read More...

Skye Bioscience, Inc., a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, announced that the U.S. Food and Drug Administration…
Read More...

Kite, a Gilead Company and Tmunity Therapeutics (Tmunity) announced that the companies have signed an agreement in which Kite will acquire Tmunity, a clinical-stage, private biotech…
Read More...

Sanofi and Innate Pharma SA announced an expansion of their collaboration, with Sanofi licensing a natural killer (NK) cell engager program targeting B7H3 from Innate’s ANKETTM …
Read More...

AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved in the European Union (EU) as monotherapy for the treatment of adult patients with advanced…
Read More...

BIOASIS TECHNOLOGIES INC., a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factors and a differentiated,…
Read More...

Fresenius Kabi announced the immediate availability in the U.S. of Lacosamide Injection, USP, a generic equivalent to VIMPAT. Fresenius Kabi Lacosamide Injection, USP is an approved…
Read More...

Gilgamesh Pharmaceuticals, a biotechnology company developing a portfolio of rapid-acting and durable treatments for depression and other mental health disorders, announced the closing…
Read More...

The European Commission (EC) has expanded the marketing authorization for Dupixent (dupilumab) in the European Union to treat adults with moderate-to-severe prurigo nodularis who are…
Read More...

Eisai Co., Ltd. announced that Eisai and Washington University School of Medicine in St. Louis have entered into a comprehensive research collaboration agreement aiming to create…
Read More...